Jaime King Fertility Journey: What Her Public Story Teaches Us About Endometriosis, PCOS, and IVF

What Jaime King Has Actually Said Publicly

Jaime King has been more specific than most celebrities who broadly reference "fertility struggles." In interviews and on social media spanning roughly 2012 through 2019, she described a grueling path to parenthood that included repeated IVF cycles, pregnancy losses, and two diagnoses that often coexist and complicate each other: endometriosis and PCOS.

Her first son, James Knight Newman, was born in October 2013. Her second son, Leo Thames Newman, arrived in February 2015. Between and before those births, she has described a process that included approximately 26 IVF cycles. That number is not typical. The average patient completes two to three cycles before either achieving a live birth or discontinuing treatment. Twenty-six cycles signals a clinical picture of significantly reduced ovarian response, implantation failure, or both.

King has also spoken about the emotional weight of repeated loss. In a 2015 interview with People magazine, she described experiencing five pregnancy losses before her second son was born. These are not minor data points. Recurrent pregnancy loss (defined by ASRM as two or more failed pregnancies) affects approximately 1-2% of couples and carries distinct diagnostic and treatment considerations.

She has named her diagnoses clearly. That matters, because many women spend years without a diagnosis while their fertility window narrows.

Why These Two Diagnoses Together Are Particularly Challenging

Endometriosis and PCOS can appear contradictory. One is associated with low or irregular ovulation; the other often causes inflammatory damage to the tubes, ovaries, and uterine lining. Having both means clinicians must balance stimulation protocols carefully.

PCOS is characterized by hyperandrogenism, chronic oligo-anovulation, and polycystic ovarian morphology on ultrasound. Endometriosis involves endometrial-like tissue implanting outside the uterus, triggering inflammation and scarring. A 2020 study in Fertility and Sterility found that women with both conditions had significantly lower IVF success rates compared to women with either diagnosis alone, particularly when endometriomas (ovarian cysts caused by endometriosis) were present.

The Disclosure Gap in Women's Health

King's willingness to name her conditions is unusual. Women have historically been told that painful periods are normal, that irregular cycles are minor inconveniences, and that difficulty conceiving is simply bad luck. ACOG estimates the average delay from symptom onset to endometriosis diagnosis is seven to ten years. That delay costs women exactly the time they cannot afford to lose.

Understanding Endometriosis and Fertility: The Clinical Picture

Endometriosis affects an estimated 10% of women of reproductive age worldwide, approximately 190 million women globally. It reduces fertility through several mechanisms: distorted pelvic anatomy from adhesions, inflammatory cytokines that damage oocytes, impaired endometrial receptivity, and in severe cases, blocked fallopian tubes.

Staging Does Not Predict Fertility Perfectly

Endometriosis is staged I through IV under the revised American Society for Reproductive Medicine classification. Stage III or IV (severe) correlates with more structural damage. But Stage I or II does not guarantee easy conception. A 2014 Cochrane review found that even minimal endometriosis reduces monthly fecundity rates compared to women without the condition.

Surgical vs. Medical Management Before IVF

For women planning IVF, the decision to surgically remove endometriomas first is not straightforward. Surgery can reduce ovarian reserve if healthy tissue is inadvertently removed alongside the cyst wall. A 2017 ASRM Practice Committee Opinion recommends a careful individualized assessment, weighing symptom severity, cyst size, ovarian reserve markers (AMH, antral follicle count), and the patient's age before proceeding with oophorectomy-sparing excision.

Medical suppression with GnRH agonists (leuprolide, for example) or progestins before IVF is sometimes used to reduce endometriotic inflammation and theoretically improve implantation. Evidence is mixed. King has not disclosed which specific protocols she used, and it would be inference to name drugs on her behalf. What is clear is that her case required an extended, iterative approach.

Understanding PCOS and Fertility: The Clinical Picture

PCOS affects 6-12% of US women of reproductive age, making it the most common endocrine disorder in this group. Fertility challenges with PCOS center primarily on anovulation: eggs are recruited but not released, or released irregularly.

Ovulation Induction: First-Line Options

For women with PCOS who are not yet at the IVF stage, ASRM guidelines published in 2023 and updated clinical guidance recommend letrozole (an aromatase inhibitor) as first-line ovulation induction, ahead of clomiphene citrate. The landmark NEJM PPCOST trial (Legro et al., 2014) found that letrozole produced higher live-birth rates (27.5% vs. 19.1%) and lower multiple-pregnancy rates than clomiphene in women with PCOS.

The Hyperstimulation Risk

Women with PCOS face a specific IVF risk: ovarian hyperstimulation syndrome (OHSS). Because the polycystic ovary contains many antral follicles, standard gonadotropin doses can trigger an exaggerated response. Severe OHSS can cause fluid shifts, clotting, and in rare cases, death. ACOG Practice Bulletin No. 194 and ASRM guidelines recommend a "freeze-all" embryo strategy in high-responders, transferring in a subsequent cycle rather than fresh, to reduce OHSS severity.

This means the raw number of IVF cycles does not map neatly onto the number of transfers. Many of King's reported cycles may have been retrieval cycles only, with embryos frozen for later transfer.

What "26 Rounds of IVF" Actually Means Medically

This figure deserves careful unpacking, because it changes how you understand what she went through.

One IVF "round" or "cycle" can mean:

• An ovarian stimulation and egg retrieval cycle
• A frozen embryo transfer (FET) cycle
• A cycle that was cancelled mid-stimulation due to poor response or OHSS risk

Per the Society for Assisted Reproductive Technology (SART), each of these is typically counted separately in clinical records, though patients often use "cycle" loosely. If King's 26 cycles include FETs, the picture is of a woman who may have had fewer retrieval cycles but required many transfer attempts before implantation succeeded.

The WomanRx "Diagnose, Stimulate, Transfer, Monitor" (DSTM) framework for women with dual endometriosis-PCOS presentations helps illustrate why cumulative cycle counts can be high even when each individual step is medically sound:

1. Diagnose. Confirm both diagnoses with laparoscopy for endometriosis staging and Rotterdam criteria for PCOS. Establish baseline AMH, antral follicle count, and uterine assessment via sonohysterogram.
2. Stimulate. Choose a gentle or antagonist protocol to manage OHSS risk. Consider GnRH antagonist co-treatment. Set a conservative cancellation threshold.
3. Transfer. Freeze all embryos in high-OHSS-risk cycles. Optimize the endometrial environment before FET, which may include progesterone supplementation and, in endometriosis cases, pre-transfer GnRH agonist downregulation.
4. Monitor. Track implantation failure patterns. After two to three failed FETs with good-quality embryos, investigate uterine factors (ERA biopsy, hysteroscopy) and consider immunological or thrombophilia workup.

This framework explains why a motivated, well-resourced patient working with skilled reproductive endocrinologists might accumulate many cycles while remaining on a medically rational path.

Fertility Medications: What Women With These Diagnoses Are Actually Prescribed

Because the article is person-focused and King has not disclosed her specific medication protocol, this section covers what women with her stated diagnoses are typically prescribed. This is clinical education, not a claim about her personal treatment.

Gonadotropins (FSH, LH, hMG)

Injectable gonadotropins stimulate the ovaries to produce multiple follicles. FDA-approved products for IVF ovarian stimulation include follitropin alfa (Gonal-F), follitropin beta (Follistim AQ), menotropins (Menopur), and recombinant LH (Luveris). Doses in women with PCOS are typically lower than average to reduce OHSS risk, often starting at 75-112.5 IU per day.

GnRH Agonists and Antagonists

GnRH agonists (leuprolide acetate, nafarelin) suppress the pituitary to prevent premature LH surges and, in endometriosis, reduce disease activity before retrieval. GnRH antagonists (cetrorelix, ganirelix) do the same job more quickly and are now the more common choice in PCOS patients because they allow for a GnRH agonist trigger shot rather than hCG, significantly reducing OHSS risk. A 2011 Cochrane review found GnRH antagonist protocols had lower OHSS rates with equivalent pregnancy rates compared to long agonist protocols.

Progesterone Supplementation

After retrieval or transfer, progesterone (vaginal suppositories, intramuscular injection, or subcutaneous injection) supports the luteal phase. Women with endometriosis may have impaired endometrial progesterone receptor expression, which is one reason progesterone supplementation protocols are particularly important in this population. A 2019 study in the Journal of Clinical Endocrinology and Metabolism documented reduced endometrial progesterone sensitivity in women with endometriosis.

Letrozole (for PCOS ovulation induction, not IVF)

As noted above, letrozole 2.5-7.5 mg on days 3-7 of the cycle is now preferred over clomiphene for women with PCOS attempting natural conception or intrauterine insemination. It is not typically used during IVF stimulation cycles.

Pregnancy and Lactation Safety: What You Must Know

This section is required reading if you are considering fertility treatment or are currently pregnant or breastfeeding.

Fertility Medications and Pregnancy Safety

Gonadotropins are used to achieve pregnancy, not during it. Once pregnancy is confirmed, gonadotropin injections stop. They are not teratogens in the conventional sense, but any pregnancy achieved via IVF should include first-trimester monitoring for complications including ectopic pregnancy, given the elevated risk in women with tubal damage from endometriosis.

GnRH agonists (leuprolide) carry an FDA category X designation for pregnancy. The FDA label for leuprolide acetate states it may cause fetal harm and is contraindicated in pregnant women. In IVF protocols, GnRH agonist exposure ends well before the transfer cycle or at the point of trigger, so ongoing pregnancy exposure is not expected under standard protocols.

Progesterone supplementation is continued through the first 8-12 weeks of an IVF pregnancy to support the luteal phase until the placenta takes over production. Vaginal micronized progesterone is generally considered safe in pregnancy; it does not carry teratogenic risk at doses used for luteal support.

Letrozole is contraindicated in pregnancy. Its prescribing information carries a clear warning against use in pregnant women, and women who take it for ovulation induction should confirm menses or a negative pregnancy test before each cycle.

Breastfeeding Considerations

Most fertility medications are intended for the preconception period and are not used while breastfeeding. Letrozole is not recommended while nursing because it reduces estrogen systemically, which can reduce milk supply. Women who are breastfeeding and wish to resume fertility treatment should discuss timing with their reproductive endocrinologist.

Contraception Requirement

This applies most directly to letrozole and clomiphene when used off-label for conditions such as hormonal suppression in endometriosis management. Any woman taking letrozole who is not actively trying to conceive should use reliable contraception. The drug is an aromatase inhibitor and can cause fetal limb defects if exposure occurs in pregnancy.

Who This Path Is Right For (and Who It Is Not)

This section is framed by life stage and specific diagnoses, not by celebrity status.

Reproductive Years, Actively Trying to Conceive

If you are in your 20s or early 30s with confirmed endometriosis and or PCOS, the clinical data supports starting with the least invasive options: letrozole with timed intercourse or IUI before moving to IVF. Your ovarian reserve is your greatest asset. ACOG recommends a full infertility workup after 12 months of unprotected intercourse (or 6 months if you are over 35).

Perimenopause and Diminished Ovarian Reserve

Women in their early-to-mid 40s with endometriosis face a different equation. Surgical excision of endometriomas at this stage carries a real risk of reducing already-declining ovarian reserve. The balance tips more quickly toward IVF with donor eggs for women who have had multiple surgeries or who have AMH levels below 0.5 ng/mL.

Women With Recurrent Pregnancy Loss

If you have experienced two or more pregnancy losses, ASRM recommends a structured evaluation including karyotyping of both partners, uterine imaging, antiphospholipid antibody testing, and thyroid function. Endometriosis-related immune dysregulation has been proposed as a contributing factor, though the evidence for specific immunological treatments remains preliminary.

Women Who Are Not Right for Aggressive IVF

Not every woman with these diagnoses needs or should pursue 26 cycles. Women with severe diminished ovarian reserve, age over 43, or multiple failed IVF cycles with own eggs may reach a point where the expected benefit no longer justifies the physical, emotional, and financial cost. A frank conversation with a reproductive endocrinologist about cumulative live-birth probability given your specific parameters is a right, not a luxury.

The Evidence Gap: What We Know About Women With Both Diagnoses

Women with dual endometriosis-PCOS presentations are underrepresented in fertility trials. Most IVF studies enroll women with a single diagnosis or unexplained infertility. The 2020 Fertility and Sterility analysis mentioned above is one of the few to directly examine combined presentations. Its finding of lower IVF success rates in this group is clinically meaningful but based on retrospective data. Prospective, adequately powered trials specifically enrolling women with both conditions do not yet exist.

This is an honest gap in the evidence. Clinicians managing these patients are making individualized decisions based on physiological reasoning and small observational studies, not high-quality RCT data. That does not mean the treatments do not work. It means the field needs better data, and women deserve to know that.

As WomanRx clinical reviewer Dr. Elena Vasquez notes: "Women with endometriosis and PCOS simultaneously are navigating two independent pathways of fertility impairment, and the clinical literature has not caught up with how common this combination actually is. Every protocol decision for these patients is an individualized judgment call, not a guideline application."

What Jaime King's Story Does (and Does Not) Tell Us

Her story normalizes the reality that fertility treatment can be long, nonlinear, and emotionally devastating even when it ultimately succeeds. That normalization has real public-health value. Women who hear her speak may recognize their own symptoms earlier and seek evaluation sooner.

Her story does not tell us which protocols work best, because we do not know her specific medications, doses, or the clinical reasoning her team used. It does not tell us that 26 cycles is the correct or necessary number for anyone else. And it does not tell us that success is guaranteed with persistence, because many women do not achieve a live birth despite multiple cycles.

The clinical takeaway is the value of early, accurate diagnosis. ACOG's 2019 committee opinion on infertility workup specifically calls out the need for timely evaluation of women with symptoms suggesting endometriosis or PCOS, rather than defaulting to watchful waiting.

A diagnosis is not a prognosis. It is a starting point for a plan.

Tracking Your Own Fertility Indicators: Practical Steps

If King's story prompted you to think about your own reproductive health, here are the specific steps with the clearest evidence base:

• Request an AMH level. Anti-Mullerian hormone reflects ovarian reserve and can be drawn on any day of your cycle. Normal range for women in their 30s is roughly 1.0-3.5 ng/mL, though labs vary. Reference ranges from the ACOG should be interpreted alongside antral follicle count on transvaginal ultrasound.
• Ask about a pelvic ultrasound. Endometriomas and polycystic ovarian morphology are both visible on transvaginal ultrasound and can prompt earlier diagnostic workup.
• Track your cycle length and pain. Cycles consistently shorter than 21 days or longer than 35 days, and pain that requires prescription analgesia, are indications for formal evaluation.
• See a reproductive endocrinologist if you have been trying for 12 months (or 6 months if you are 35 or older). Do not wait for a primary care provider to refer you. You can self-refer to most reproductive endocrinology practices.

The 2021 SART national data shows a live-birth rate per intended egg retrieval of approximately 46% for women under 35, falling to 22% for women aged 38-40 and 5% for women over 42. Time is a concrete clinical variable. Act on it.